Trial intelligence / Profile preview

Sevasemten in Becker Muscular Dystrophy

NCT05291091Phase 2Completed

Start
Nov 2022
Primary completion
Sep 2026
Modality
Small Molecules
Countries
12
01

Overview

A Phase 2 trial of sevasemten in Becker muscular dystrophy (BMD). Started Nov 2022; status: completed.

02

Drugs

sevasemten
03

Conditions

Becker muscular dystrophy (BMD)

Beyond the preview

Go deeper on NCT05291091.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05291091.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call